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Echocardiographic evaluation of left ventricular function after taking amlodipine 
for hypertension and chronic stable angina on 507 rural human subjects 





This is a prospective, community based, 
single blind, monocentric, clinical study 
performed in a community based healthcare 
centre, Chatkhil, Noakhali for the period from 
June 23, 2006 to September 21, 2008. Patients 
of hypertension & IHD (chronic stable 
angina) were selected for study, age limit 20-
80 years, both genders was included; sample 
size 507. The prime objective is to study the 
efficacy of amlodipine on left ventricular 
function on hypertension & ischaemic heart 
disease. Patients were evaluated clinically & 
then investigated by X-Ray, ECG, 
Echocardiography. Amlodipine therapies (5 
mg daily) was given with or without other 
medications followed by echo-evaluation of 
LV function for 9-12 months LV-EF & LV 
mass/BSA were measured very accurately. 
Among 507, male 355 (70.01%) & female 
152 (29.98%). 50-59 years age group was 
affected much (210 cases, 41.42%). Second 
affected age group is 60-69 years (107 cases, 
21.10%). Service holders & businessmen 
were affected much (135 cases- 26.62%, 134 
cases- 26.42%). Normal LV-EF was observed 
in 95 (18.73%) & 114 cases (23.26%) before 
& after drug therapy. Besides normal LV 
mass/BSA was observed in 50 (9.86%) & 67 
(13.67%) cases respectively before & after 
treatment. So it is concluded that amlodipine, 
a third generation CCB effectively control 













 thus improves LV function (LV-EF). 
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Introduction 
Calcium (Ca++) is required for contraction of 
cardiac & smooth muscle, also responsible for 
propagation of cardiac impulse; Calcium 
Channel Blockers (CCBs) block the influx of 
calcium into cells. This relaxes the muscles in 
the walls of arteries resulting in dilatation.1 
This lowers the blood pressure and improves 
the blood supply to the heart muscle. All of 
these effects allow the heart to work with 
reduced blood supply together with relief of 
anginal pain.2 
 
Calcium Channel Blockers (CCBs) may be 
divided into benzothiazepine (diltiazem); 
phenylalkylamine (verapamil); and 
dihydropyridines (first generation: Nifedipine, 
nicardipine, felodipine, nisoldipine; second 
generation: isradipine, nimodipine; third 
generation: amlodipine, lacidipine etc). 
 
Amlodipine is a third generation CCB with 
long half-life. It has interaction with specific 
high affinity binding sites in the calcium 
channel complex. It maintains therapeutic 
efficacy throughout 24 hours. It has less 
negative inotrophic and chronotrophic action, 
having lack of clinically, relevant increase in 
cardiac or peripheral sympathetic activity. It 
has higher lipophilicity; reflex tachycardia is 
minimal, relatively safe in heart failure.3 
 
The L-type calcium channel is the dominant 
type in cardiac & smooth muscle. The 
calcium channel blockers act from the inner 
side of the membrane and bind more 
effectively to channels in depolarizing 
membranes. 
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In the cardiac myocyte, Ca++ binds to 
troponin and reduces inhibitory effects of 
troponin on contraction, favouring muscle 
contraction. CCBs reduce transmembrane 
movement of Ca++, reduce the amount 
reaching intracellular sites and therefore 
reduce vascular smooth muscle tone. 
 
Amlodipine has got minimal or no effect on 
AV conduction.4 
 
CCBs have direct negative inotrophic effects 
and showed some benefits on haemodynamic 
parameters alone or in combination with ACE 
inhibitors. Amlodipine has got potentially 
beneficial effects on hypertension and 
coronary artery disease especially stable 
angina. But amlodipine showed minimal 
beneficial effects in patients with heart failure 
which was observed on large, randomized, 
placebo-controlled trials.5 
 
Aims and objectives 
The objectives were- 
i. To study the efficacy of amlodipine on left 
ventricular function in hypertension. 
ii. To study the efficacy of amlodipine on left 
ventricular function in ischaemic heart 
disease (stable angina). 
iii. To evaluate any side effects of amlodipine 
used for HTN & stable angina. 
iv. Echocardiographic evaluation of LV 
functions after amlodipine therapy in HTN & 
IHD. 
v. Finally to provide some new information 
on amlodipine therapy in this regard. 
 
Materials and methods 
It is a prospective, community based, single 
blind, mono-centric, clinical study performed 
in a Community Health Care Centre, 
Chatkhil, Noakhali from 23.06.2006 to 
21.09.2008. 
 
A larger geographical area of Noakhali 
district i.e. Chatkhil, Sonaimuri, Begumgonj 
and part of Lakhipur and Comilla districts 
were fairly covered in this study. 
 
All patients attending the OPD were screened. 
Patients of hypertension & IHD (stable 
angina) were selected for study. Age limit 
was 20-80 years; no gender variation; 
associated heart failure was not a 
contraindication for inclusion. Consent was 
taken from all patients or relatives prior entry 
to study. 
 
After clinical case selection, patients were 
investigated by X-ray, ECG, Echo, blood 
glucose and lipid profile. Then amlodipine 
therapy (5 mg daily) was given with other 
medications followed by echocardiographic 
evaluation of LV function every 2-3 months 
interval. 
 
For 2D & M-mode echocardiography we used 
ALOKA SSD-1100 equipment. Left 
ventricular function was evaluated by the 
following parameters: wall thickness, 
chamber dimension, wall motion abnormality, 
ejection fraction, stroke index, LV mass/BSA 
etc. 
 
Some LV parameters 
 
A. Stroke Volume (SV)   
SV Vold-Vols 
Vold End diastolic volume in ml 
Vols End systolic volume in ml 
LVEDV 90-140 ml 
LVESV 27-85 ml 
SV 50-100 ml 
 
 
B. Stroke Index in ml/m2(SI)   
S.I. SV/BSA 
SV Stroke volume in ml 
BSA Body Surface Area in m2 
Example SV-75 ml;BSA- 1.5 m2 
So, S.I.=75/1.5 = 50 ml/m2   
 
C. Cardiac Index in L/min/m2(CI)   
C.I. CO/BSA 
CO Cardiac output in L/min 
BSA Body Surface Area in m2 
Example CO-5 L/min; BSA- 1.5 m2 
So, C.I.=5/1.5 =3.3 L/min/m2   
 
D. LV mass- cube (gm) = 1.04  [(IVS+LVID+PW)3-(LVID)3] 
(measurement in cm)   
Example IVS-1.0 cm; LVID- 4.5 cm 
  PW-1.0 cm) 
So, LV mass-cube=190.84 gm   
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E. LV mass= 0.80 (LV mass cube)+ 0.60 (ASE convention)  
American Scociety of Echocardiography  
Example,LV mass cube 190.84 gm 












Various data obtained from the study were 
presented below using various tables, figures 
and graphs. 
Table 1: Gender distribution of patients (n=507) 
Gender Number Percent 
Male 355 70.01 
Female 152 29.98 
Table 2: Age distribution of patients 
Age in years Number Percent 
20-29 05 0.98 
30-39 45 8.87 
40-49 97 19.13 
50-59 210 41.42 
60-69 107 21.10 
70-79 43 8.48 
Table 3: Occupation of patients (n=507) 
Occupation Number Percent 
Farmer 02 0.39 
Day labourer 31 6.11 
Service holder 135 26.62 
Teachers 96 18.93 
Fishermen 37 7.29 
Beggars 01 0.19 
House-wives 59 11.63 
Businessmen 134 26.42 
Others 12 2.36 
Table 4: Disease profile in study subjects (n=507) 
Disease profile Number Percent 




HTN + IHD 
(Co-exist) 
96 18.93 
Table 5: Gradings of hypertension (n=345) 
Gradings Number Percent 
Mild 84 24.34 
Moderate 157 45.50 
Severe 104 30.14 
Table 6: Echo-evaluation of LV-EF before treatment (n=507) 
LV Number Percent 
Normal (60-75%) 95 18.73 




Severe dysfunction (30-39%) 114 22.48 
Very severe dysfunction 
(<30%) 
87 17.15 
Table 7: Echo-evaluation of LV-EF after treatment (n=490) 
LVEF Number Percent 
Normal  114 23.26 
Mild dysfunction 110 22.44 
Moderate dysfunction 90 18.36 




Drop out 17 3.35 
F.    LV mass (Penn Convention) = (LV mass cube) – 14 
G.   LV mass/BSA : 125–150 gm/m2 
H.   Ejection fraction in percent (EF) 
       EF                                   100 (Vold–Vols) / Vold 
       Vold                                End diastolic volume in cm3 
       Vols                                 End systolic volume in cm3 
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Figure 1: Bar diagram showing LV-EF before & after treatment 
Table 8: Follow-up Echo-evaluation of LV mass/BSA before treatment (n=507) 













Suggested cut-off point for LVH is 125g/BSA 
 
Figure 2: Bar diagram showing LV mass/BSA before & after treatment 
Table 9: Echo-evaluation of LV mass/BSA after treatment (n=490) 
LV mass/BSA (g/m2) Number Percent 
Normal  67 13.67 
Grade-I hypertrophy 101 20.61 
Grade-II hypertrophy 184 37.55 
Grade-III hypertrophy 138 28.16 





For hypertensive patients, one should select 
the appropriate medication to control 
hypertension. Hypertension is one of the most 
prevalent risk factor for cardiovascular 
disease, affecting as many as 800 million 
people world wide. 
 
Amlodipine effectively reduces the 
cardiovascular risk factors related to 
hypertension. 
 
Table 1 shows the gender distribution of 
patients (n=507); male- 355 (70.01%), 
female- 152 (29.98%). We have observed 
prevalence of hypertension and coronary 
artery disease much more in males rather than 
females; which was supported by 
Scandanavian research group in 2007.6 
 
Table 2 shows age distribution of patients. 
Maximum affected age group in 50-59 years 
(210 cases, 41.42%); next common affected 
group in 60-69 years (107 cases, 21.10%). 
Malhotra and Co-workers7 also found the 
similar incidence in European Community; 
50-59 years, 43.42% & 60-69 years age group 
23.25% respectively.7 
 
Various occupations of patients were showed 
in table 3. Maximum incidence was observed 
in service holders (135 cases, 26.62%) & 
businessmen (134 cases, 26.42%). Other 
researchers also observed the same 
phenomena in white, as well as black races.8 
 
Table 4 narrated the disease profile in study 
subjects (n=507) i.e. only hypertension-249 
cases (49.11%), only IHD (stable angina)- 
162 cases (31.95%) & associated HTN plus 
IHD- 96 cases (18.93%). 
 
Gradings of hypertension were done on 345 
cases: 
a) Mild- 84 cases (24.34%) 
b) Moderate- 157 cases (45.50%) 
c) Severe- 104 cases (30.14%). 
 
In our community population prevalence of 
moderate hypertension is higher, which was 
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supported by Kamango, Picarno & other Co-
workers in 2006.9 
 
Left ventricular function of the study-subjects 
suffering from hypertension & chronic stable 
angina (n=507) was evaluated by 
echocardiography. Though various methods 
of calculation are available, simplest formula 
of calculating LV-EF through POMBO 
method was adopted. 
 
Table 6 & 7 showed the comparative study of 
echo-evaluation of LV-EF before & after 
amlodipine treatment. Before treatment 
normal LV-EF was observed on 95 cases 
(18.73%). After treatment it has become 114 
cases (23.26%). This rise of 19 cases (4.51%) 
is due to control of BP resulting from 
amlodipine therapy. Before treatment severe 
dysfunction was observed in 114 cases 
(22.48%); but after treatment it has come 
down to 99 cases (20.20%). This reduction 
(2.28%) of LV systolic dysfunction is due to 
drug therapy. It was observed by Panthorian 
and Co-workers in 2007 i.e. 3.31%.10 
 
Table 8 & 9 showed the comparative study of 
LV mass/BSA in study subjects just before & 
after amlodipine therapy. Suggested cut off 
point for LVH is 125g/BSA. 
 
Table 8 showed different gradings of LV 
hypertrophy where grade-I: LVH- 107 cases 
(21.10%), grade-II: LVH- 193 cases 
(38.06%), grade-III: LVH- 157 cases 
(30.96%). 
 
Despite drop out of 17 cases (3.35%), the 
scenario has been changed after control of BP 
with amlodipine with or without other 
medications i.e. grade-I: LVH- 101 cases 
(20.61%), grade-II: LVH- 184 cases 
(37.55%), grade-III: LVH- 138 cases 
(28.16%). 
 
Reduction of LV mass/BSA index was 
observed in the study groups- Quinkibay and 
Co-worker in 2006,11 Ducketty & Pathania in 
200712 and also in LV mass/BSA trial in 
Scandanavian population in 2008.13 
 
Conclusion 
Amlodipine is a third generation calcium 
channel blocker with favourable 
pharmacokinetic profile. For its much higher 
affinity for vascular calcium channels, it is 
particularly useful in treating hypertension. 
Due to its intrinsic natriuretic effect, it is 
proven effective for mild, moderate & severe 
hypertension. It provides 24 hours angina 
protection including morning hours. It is also 
effective in variant angina. From various 
studies it was proved that amlodipine is 
efficacious in improving left ventricular 
function in hypertensive and ischaemic heart. 
So adjunct to other usual medications we 
shall suggest to add low dose CCB i.e. 
amlodipine with a view to improve left 
ventricular function, unless contraindicated; 




This research work was conducted with the 
compliments of a Pharmaceuticals company; 
but neither influencing the results of study, 
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